HepaCAM inhibits cell proliferation and invasion in prostate cancer by suppressing nuclear translocation of the androgen receptor via its cytoplasmic domain Corrigendum in /10.3892/mmr.2022.12746

Deng,Qingfu; Luo,Li; Quan,Zhen; Liu,Nanjing; Du,Zhongbo; Sun,Wei; Luo,Chunli; Wu,Xiaohou

doi:10.3892/mmr.2019.9841

HepaCAM inhibits cell proliferation and invasion in prostate cancer by suppressing nuclear translocation of the androgen receptor via its cytoplasmic domain

Corrigendum in: /10.3892/mmr.2022.12746

Authors:
- Qingfu Deng
- Li Luo
- Zhen Quan
- Nanjing Liu
- Zhongbo Du
- Wei Sun
- Chunli Luo
- Xiaohou Wu
View Affiliations

Affiliations: Department of Urology, First Affiliated Hospital of Chongqing Medical University, Chongqing 400042, P.R. China, Key Laboratory of Diagnostics Medicine Designated by The Ministry of Education, Chongqing Medical University, Chongqing 400042, P.R. China
Published online on: January 10, 2019 https://doi.org/10.3892/mmr.2019.9841
Pages: 2115-2124
Copyright: © Deng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocyte cell adhesion molecule (HepaCAM) is a tumour suppressor. However, the mechanism of HepaCAM function in prostate cancer (PCa) remains unknown. In the present study, HepaCAM, androgen receptor (AR) and Ran were analysed in 46 PCa tissue samples using immunohistochemistry. Subsequently, the influence of HepaCAM and its cytoplasmic domain on cell proliferation, migration, and invasion, and associated proteins was examined using MTT, wound healing, Transwell and western blotting assays, respectively. Furthermore, nuclear translocation of AR and Ran was analysed using immunofluorescence and Western blot assays. The results demonstrated that HepaCAM expression was reduced in PCa, and there was an association between downregulation of HepaCAM and changes in the distribution of AR and Ran. Furthermore, HepaCAM, specifically the cytoplasmic domain, was involved in cell proliferation, migration and invasion. Nuclear translocation of AR was dependent on HepaCAM and its cytoplasmic domain. Additionally, HepaCAM suppression of the nuclear translocation of AR occurred via Ran. The results suggest that HepaCAM and its cytoplasmic domain suppress the nuclear translocation of AR via Ran in PCa. The cytoplasmic domain of HepaCAM may serve as a novel target for therapy in PCa.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
2	Chung Moh M, Hoon Lee L and Shen S: Cloning and characterization of hepaCAM, a novel Ig-like cell adhesion molecule suppressed in human hepatocellular carcinoma. J Hepatol. 42:833–841. 2005. View Article : Google Scholar : PubMed/NCBI
3	Moh MC, Zhang T, Lee LH and Shen S: Expression of hepaCAM is downregulated in cancers and induces senescence-like growth arrest via a p53/p21-dependent pathway in human breast cancer cells. Carcinogenesis. 29:2298–2305. 2008. View Article : Google Scholar : PubMed/NCBI
4	Xu B, He Y, Wu X, Luo C, Liu A and Zhang J: Exploration of the correlations between interferon-γ in patient serum and HEPACAM in bladder transitional cell carcinoma, and the interferon-γ mechanism inhibiting BIU-87 proliferation. J Urol. 188:1346–1353. 2012. View Article : Google Scholar : PubMed/NCBI
5	Xun C, Luo C, Wu X, Zhang Q, Yan L and Shen S: Expression of hepaCAM and its effect on proliferation of tumor cells in renal cell carcinoma. Urology. 75:828–834. 2010. View Article : Google Scholar : PubMed/NCBI
6	Zhang QL, Luo CL, Wu XH, Wang CY, Xu X, Zhang YY, Liu Q and Shen SL: HepaCAM induces G1 phase arrest and promotes c-Myc degradation in human renal cell carcinoma. J Cell Biochem. 112:2910–2919. 2011. View Article : Google Scholar : PubMed/NCBI
7	Song X, Wang Y, Du H, Fan Y, Yang X, Wang X, Wu X and Luo C: Overexpression of HepaCAM inhibits cell viability and motility through suppressing nucleus translocation of androgen receptor and ERK signaling in prostate cancer. Prostate. 74:1023–1033. 2014. View Article : Google Scholar : PubMed/NCBI
8	Wang X, Chen E, Tang M, Yang X, Wang Y, Quan Z, Wu X and Luo C: The SMAD2/3 pathway is involved in hepaCAM-induced apoptosis by inhibiting the nuclear translocation of SMAD2/3 in bladder cancer cells. Tumour Biol. 37:10731–10743. 2016. View Article : Google Scholar : PubMed/NCBI
9	Wen S, Chang HC, Tian J, Shang Z, Niu Y and Chang C: Stromal androgen receptor roles in the development of normal prostate, benign prostate hyperplasia, and prostate cancer. Am J Pathol. 185:293–301. 2015. View Article : Google Scholar : PubMed/NCBI
10	Scher HI and Sawyers CL: Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 23:8253–8261. 2005. View Article : Google Scholar : PubMed/NCBI
11	Taplin ME and Balk SP: Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem. 91:483–890. 2004. View Article : Google Scholar : PubMed/NCBI
12	Chen Y, Clegg NJ and Scher HI: Anti-androgens and androgen-depleting therapies in prostate cancer: New agents for an established target. Lancet Oncol. 10:981–991. 2009. View Article : Google Scholar : PubMed/NCBI
13	Attard G, Cooper CS and de Bono JS: Steroid hormone receptors in prostate cancer: A hard habit to break? Cancer Cell. 16:458–462. 2009. View Article : Google Scholar : PubMed/NCBI
14	Dehm SM and Tindall DJ: Androgen receptor structural and functional elements: Role and regulation in prostate cancer. Mol Endocrinol. 21:2855–2863. 2007. View Article : Google Scholar : PubMed/NCBI
15	Knudsen KE and Scher HI: Starving the addiction: New opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res. 15:4792–4798. 2009. View Article : Google Scholar : PubMed/NCBI
16	Adam SA and Gerace L: Cytosolic proteins that specifically bind nuclear location signals are receptors for nuclear import. Cell. 66:837–847. 1991. View Article : Google Scholar : PubMed/NCBI
17	Rexach M and Blobel G: Protein import into nuclei: Association and dissociation reactions involving transport substrate, transport factors, and nucleoporins. Cell. 83:683–692. 1995. View Article : Google Scholar : PubMed/NCBI
18	Weis K, Dingwall C and Lamond AI: Characterization of the nuclear protein import mechanism using Ran mutants with altered nucleotide binding specificities. EMBO J. 15:7120–7128. 1996. View Article : Google Scholar : PubMed/NCBI
19	Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, Freedland SJ, Greene K, Klotz LH, Makarov DV, et al: Clinically localized prostate cancer: AUA/ASTRO/SUO Guideline. Part I: Risk stratification, shared decision making, and care options. J Urol. 199:683–690. 2018. View Article : Google Scholar : PubMed/NCBI
20	Wang Y, Wu X, Ou L, Yang X, Wang X, Tang M, Chen E and Luo C: PLCepsilon knockdown inhibits prostate cancer cell proliferation via suppression of Notch signalling and nuclear translocation of the androgen receptor. Cancer Lett. 362:61–69. 2015. View Article : Google Scholar : PubMed/NCBI
21	Wang Q, Luo C, Wu X, Du H, Song X and Fan Y: hepaCAM and p-mTOR closely correlate in bladder transitional cell carcinoma and hepaCAM expression inhibits proliferation via an AMPK/mTOR dependent pathway in human bladder cancer cells. J Urol. 190:1912–1918. 2013. View Article : Google Scholar : PubMed/NCBI
22	Wang L, Hou Y, Sun Y, Zhao L, Tang X, Hu P, Yang J, Zeng Z, Yang G, Cui X and Liu M: c-Ski activates cancer-associated fibroblasts to regulate breast cancer cell invasion. Mol Oncol. 7:1116–1128. 2013. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Becker KF, Rosivatz E, Blechschmidt K, Kremmer E, Sarbia M and Höfler H: Analysis of the E-cadherin repressor Snail in primary human cancers. Cells Tissues Organs. 185:204–212. 2007. View Article : Google Scholar : PubMed/NCBI
25	Bennett NC, Gardiner RA, Hooper JD, Johnson DW and Gobe GC: Molecular cell biology of androgen receptor signalling. Int J Biochem Cell Biol. 42:813–827. 2010. View Article : Google Scholar : PubMed/NCBI
26	Taplin ME and Balk SP: Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem. 91:483–490. 2004. View Article : Google Scholar : PubMed/NCBI
27	Quan Z, He Y, Luo C, Xia Y, Zhao Y, Liu N and Wu X: Interleukin 6 induces cell proliferation of clear cell renal cell carcinoma by suppressing hepaCAM via the STAT3-dependent up-regulation of DNMT1 or DNMT3b. Cell Signal. 32:48–58. 2017. View Article : Google Scholar : PubMed/NCBI
28	Moh MC, Zhang C, Luo C, Lee LH and Shen S: Structural and functional analyses of a novel ig-like cell adhesion molecule, hepaCAM, in the human breast carcinoma MCF7 cells. J Biol Chem. 280:27366–27374. 2005. View Article : Google Scholar : PubMed/NCBI
29	Geng HT, Cao RJ, Cheng L and Liu CY: Overexpression of hepatocyte cell adhesion molecule (hepaCAM) inhibits the proliferation, migration, and invasion in colorectal cancer cells. Oncol Res. 25:1039–1046. 2017. View Article : Google Scholar : PubMed/NCBI
30	Du Z, Li L, Sun W, Wang X, Zhang Y, Chen Z, Yuan M, Quan Z, Liu N, Hao Y, et al: HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in vitro. Int J Oncol. 53:99–112. 2018.PubMed/NCBI
31	Bluemn EG and Nelson PS: The androgen/androgen receptor axis in prostate cancer. Curr Opin Oncol. 24:251–257. 2012. View Article : Google Scholar : PubMed/NCBI
32	Ardiani A, Gameiro SR, Kwilas AR, Donahue RN and Hodge JW: Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway. Oncotarget. 5:9335–9348. 2014. View Article : Google Scholar : PubMed/NCBI
33	Shank LC, Kelley JB, Gioeli D, Yang CS, Spencer A, Allison LA and Paschal BM: Activation of the DNA-dependent protein kinase stimulates nuclear export of the androgen receptor in vitro. J Biol Chem. 283:10568–10580. 2008. View Article : Google Scholar : PubMed/NCBI
34	Matchett KB, McFarlane S, Hamilton SE, Eltuhamy YS, Davidson MA, Murray JT, Faheem AM and El-Tanani M: Ran GTPase in nuclear envelope formation and cancer metastasis. Adv Exp Med Biol. 773:323–351. 2014. View Article : Google Scholar : PubMed/NCBI